Risk factors for death of patients with cystic fibrosis awaiting lung transplantation

被引:129
作者
Belkin, RA
Henig, NR
Singer, LG
Chaparro, C
Rubenstein, RC
Xie, SX
Yee, JY
Kotloff, RM
Lipson, DA
Bunin, GR
机构
[1] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Pulm, Philadelphia, PA 19104 USA
[2] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Allergy, Philadelphia, PA 19104 USA
[3] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Allergy, Philadelphia, PA 19104 USA
[4] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Crit Care, Philadelphia, PA 19104 USA
[5] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Biostat, Philadelphia, PA 19104 USA
[6] Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA
[7] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
[8] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
[9] Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA
[10] Univ Toronto, Div Respirol, Hlth Network, Toronto, ON, Canada
[11] Univ Toronto, Toronto, ON, Canada
关键词
cystic fibrosis; lung transplantation; survival;
D O I
10.1164/rccm.200410-1369OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: The optimal timing for listing of cystic fibrosis patients for lung transplantation is controversial. Objectives: We conducted a retrospective cohort study of 343 patients listed for lung transplantation at four academic medical centers to identify risk factors for death while awaiting transplantation. Methods: Data on possible risk factors were abstracted from medical records. Measurements: Time to death, patient demographic characteristics, and risk factors for death while awaiting transplantation were assessed. Univariate and multivariate survival analyses were performed using Cox regression. Results: By univariate analyses, FEV1 <= 30% predicted (HR, 3.8; 95% CI, 2.0-7.5), Pa-CO2 >= 50 mm Hg (HR, 1.85; 95% CI, 1.1-3.0), and shorter height (HR, 1.8; 95% Cl, 1.1-3.0) were associated with a higher risk of death. Referral from an accredited cystic fibrosis center was associated with a lower risk (HR, 0.53; 95% Cl, 0.30-0.92). The final multivariate model included referral from an accredited cystic fibrosis center (HR, 0.5; 95% Cl, 0.3-1.0) and listing year after 1996 (HR, 0.4; 95% Cl, 0.2-0.7); both were associated with a lower risk of death. FEV1 <= 0% predicted (HR, 6.8; 95% CI, 2.4-19.3), Pa-CO2 >= 50 mm Hg (HR, 6.9; 95% CI, 1.5-32.1), and use of a nutritional intervention (HR, 2.3; 95% Cl, 1.3-4.1) were associated with increased risk. Patients with FEV1 > 30% predicted had a higher risk of death only when their Pa-CO2 was >= 50 mm Hg (HR, 7.0; 95% Cl, 1.5-32), while the increased risk of death with FEV1 <= 30% was not further influenced by the presence of hypercapnia. Conclusions: We identified risk factors for waiting list mortality that could impact on transplant listing and allocation guidelines.
引用
收藏
页码:659 / 666
页数:8
相关论文
共 44 条
[11]   GENDER DIFFERENCES IN CYSTIC-FIBROSIS - PSEUDOMONAS-AERUGINOSA INFECTION [J].
DEMKO, CA ;
BYARD, PJ ;
DAVIS, PB .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (08) :1041-1049
[12]   Timing of referral for lung transplantation for cystic fibrosis -: Overemphasis on FEV1 may adversely affect overall survival [J].
Doershuk, CF ;
Stern, RC .
CHEST, 1999, 115 (03) :782-787
[13]  
Egan T. M., 2001, Journal of Heart and Lung Transplantation, V20, P242, DOI 10.1016/S1053-2498(00)00547-7
[14]   Burkholderia cepacia in cystic fibrosis -: Variable disease course [J].
Frangolias, DD ;
Mahenthiralingam, E ;
Rae, S ;
Raboud, JM ;
Davidson, AGF ;
Wittmann, R ;
Wilcox, PG .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (05) :1572-1577
[15]   Pulmonary hypertension and cardiac function in adult cystic fibrosis - Role of hypoxemia [J].
Fraser, KL ;
Tullis, DE ;
Sasson, Z ;
Hyland, RH ;
Thornley, KS ;
Hanly, PJ .
CHEST, 1999, 115 (05) :1321-1328
[16]   IMPROVED RESPIRATORY PROGNOSIS IN PATIENTS WITH CYSTIC-FIBROSIS WITH NORMAL FAT-ABSORPTION [J].
GASKIN, K ;
GURWITZ, D ;
DURIE, P ;
COREY, M ;
LEVISON, H ;
FORSTNER, G .
JOURNAL OF PEDIATRICS, 1982, 100 (06) :857-862
[17]   Allergic bronchopulmonary aspergillosis in cystic fibrosis - Reported prevalence, regional distribution, and patient characteristics [J].
Geller, DE ;
Kaplowitz, H ;
Light, MJ ;
Colin, AA .
CHEST, 1999, 116 (03) :639-646
[18]   Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis [J].
Goss, CH ;
Otto, K ;
Aitken, ML ;
Rubenfeld, GD .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (03) :356-361
[19]   A prognostic model for the prediction of survival in cystic fibrosis [J].
Hayllar, KM ;
Williams, SGJ ;
Wise, AE ;
Pouria, S ;
Lombard, M ;
Hodson, ME ;
Westaby, D .
THORAX, 1997, 52 (04) :313-317
[20]   Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease [J].
Hosenpud, JD ;
Bennett, LE ;
Keck, BM ;
Edwards, EB ;
Novick, RJ .
LANCET, 1998, 351 (9095) :24-27